A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLC).
The team investigated the sensitivity of small cell lung cancer cells to AZD3965 and showed that in those cells lacking an alternate lactate transporter, MCT4, the drug had an effect.